Trial
NCT01177540
Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Eisai Inc.
Collaborators
—
Condition
Pediatric Acute Myelogenous Leukemia (AML)
Intervention
Decitabine
Why stopped
The study was terminated early due to enrollment difficulties and the futility of observing differences in remission rate between treatment arms.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-28